Ionis Pharmaceuticals, Inc. Share Price & Technical Analysis
IONS · $76.07 (+0.67%)
Healthcare / Biotechnology
$76.07
+0.67%
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditar…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
1% return in May, 5% avg return in past 3 year May month.
-4% return in 2026, 23% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 4% | -2% | -5% | -1% | 1% | – | – | – | – | – | – | – | -4% |
| 25 | -10% | 6% | -9% | 2% | 8% | 17% | 7% | 0% | 33% | 14% | 11% | -4% | 74% |
| 24 | 0% | -13% | -4% | -5% | -9% | 25% | 4% | -4% | -16% | -4% | -8% | -3% | -36% |
| 23 | 5% | -9% | -1% | -1% | 16% | -1% | 1% | -3% | 12% | -2% | 11% | 3% | 31% |
| 22 | 4% | 9% | 13% | 0% | 0% | 1% | 1% | 13% | 4% | -1% | -8% | -7% | 29% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Uptrend
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$12.66B
P/E ratio
—
52W high
$86.74
52W low
$32.00
Volume
7,10,882
Beta
0.38
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Ionis Pharmaceuticals, Inc. share price today?
- Ionis Pharmaceuticals, Inc. (IONS) last traded around $76.07 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IONS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IONS. Download the app for real-time alerts.
- How can I analyze Ionis Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.